Skip to main content

Clinical trial EMR 200066-007

A multicentre, open label, randomized Phase II trial of the MEK inhibitor pimasertib or dacarbazine in previously untreated subjects with NRas mutated locally advanced or metastatic malignant cutaneous melanoma

Organ Skin
Trial status Trial closed
Trial type
Interventional with experimental drug
Phase Trial phase 2
Academic trial Non
Sponsor Merck Serono
EudraCT Identifier 2012-002669-37
Inclusion criteria N-Ras mutated
Last update